12400 High Bluff Drive
121 articles with Evofem Biosciences
Evofem Biosciences, Inc. announced today that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data now expected in Late 2018
Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018
Evofem Biosciences, Inc. will hold a conference call to discuss financial results and business highlights for the quarter ended June 30, 2018
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
Evofem Biosciences, Inc. announced today that Saundra Pelletier, CEO, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 3:30 p.m. EDT in New York City.
The shares and pre-funded warrants are being sold at a public offering price of $4.69 per share and $4.68 per pre-funded warrant
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the launch of an underwritten public offering of $40.0 million of its common stock
Evofem Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® vaginal gel for the prevention of urogenital chlamydia in women.
The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.
Evofem Biosciences Completes Enrollment of Phase III Contraceptive Trial of Amphora Ahead of Schedule
Trial data is expected in the first quarter of 2019.
Evofem Biosciences Announces First Patient Enrolled in Phase Ib/III STI Trial of Amphora and Expects Phase III Contraceptive Clinical Trial Data First Quarter 2019
Evofem Biosciences today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.
The merged company will operate as Evofem Biosciences and will focus on the continued development and commercialization of women's healthcare products.
The merger will position the combined company with an opportunity to become a leading women's health company that develops and commercializes novel products.
Evofem Announces First Patient Enrolled In A Phase III Clinical Trial Of AMPHORA (L-Lactic Acid, Citric Acid, And Potassium Bitartrate) For Prevention Of Pregnancy
Evofem Announces First Patient Enrolled In A Clinical Trial To Determine The Effect And Duration Of Amphora Gel On Vaginal Ph
Evofem CEO, Saundra Pelletier, To Address The Cavendish Global Health Impact Forum At BIOCOM On Innovations In Reproductive Health Care Around The Globe